Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

This finding suggests that semaglutide can not only prevent kidney damage but also halt or slow its progression, offering hope for those at risk of kidney failure. Beyond kidney benefits ...

Research on the gut microbiome has triggered a 'revolution' in nutritional science, and in the last few years, dietary fiber ...

A new study showed that semaglutide may help with alcohol use disorder Cara Lynn Shultz is a writer-reporter at PEOPLE. Her work has previously appeared in Billboard and Reader's Digest.

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.

Multiple studies have highlighted the glycemic, weight, and cardiac benefits of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1-RA), treatment in patients with or without type 2 ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...